O013 HYPOGLYCEMIA DETECTION USING A NON-INVASIVE CONTINUOUS BLOOD GLUCOSE MONITORING DEVICE IN INTENSIVE CARE

glycemic control. Blood samples were taken at 1st, 3rd, 6th, 9th and 12th days. We determined the circulating levels of ADMA, SDMA, arginine, interleukin-6, tumornecrosis-factor alpha and c-reactive-protein. At each sampling time the sequential organ failure assessment (SOFA) was scored. All data were analyzed on an intention-to-treat basis, and differences between groups and over time were assessed by means of a linear mixed model for repeated measures. Results: The control and treatment groups did not differ at admission; during the study they received the same energy intake (20.3±16.3 vs 18.9±2.7 kcal/kg/day, p = 0.74). Glycemia (110.4±17.3 vs 163.0±28.9mg/dl, p < 0.001) and insuline supply (74.5±141.1 vs 38.8±44.8 IU/day, p = 0.02) were statistically different. No differences were found in high plasma levels of ADMA (TGC 1.08±0.42 vs control 1.08±0.41mmol/L, p = 0.812) and SDMA (TGC 2.37±1.53 vs control 2.07±1.63mmol/L, p = 0.374) during the ICU stay. The clinical course, as indicated by markers of inflammation, average and maximum SOFA, ICU stay, and ICU and 90-day mortality were not different between groups. Conclusion: TGC, while achieving glucose control, did not reduce ADMA or SDMA in high-risk septic patients, fed with no more than 25 kcal/kg per day to limit ventilatory demand and to simplify glucose control.